Cellular proliferation and/or survival advantages due to gene mutations may also explain the recent finding that CHIP-associated mutations have been identified in back-tracked samples from patients who developed an MDS after chemo/radio-therapy for a previous cancer or an autoimmune disease (t-MN) [28]. The gene discussed is STUB1; the disease is cancer.